RxSight (RXST) Debt Ratio (2020 - 2023)

RxSight (RXST) posted Debt Ratio of 0.13 for Q2 2023, down 36.17% on a QoQ basis from 0.2 in Q1 2023, and down 49.21% year-over-year from 0.25 in Q2 2022.

RxSight (RXST) Debt Ratio (2020 - 2023) Analysis & Trends

RxSight's Debt Ratio history runs 4 years deep, the most recent figure standing at 0.13 for Q2 2023.

  • Quarterly Debt Ratio fell 49.21% year-over-year to 0.13 in Q2 2023, while the trailing twelve-month figure through Jun 2023 was 0.13 (down 49.21% YoY) and the FY2022 annual result came in at 0.27, up 29.66% from the prior year.
  • Debt Ratio was 0.13 for Q2 2023 at RxSight, down from 0.2 in the prior quarter.
  • Across five years, Debt Ratio topped out at 0.42 in Q2 2021 and bottomed at 0.13 in Q2 2023.
  • A 4-year average of 0.24 and a median of 0.23 in 2022 frame the typical range for Debt Ratio.
  • Annual changes were most pronounced in 2022 — Debt Ratio soared 38.13% — and 2023, when it slumped 49.21%.
  • RxSight's Debt Ratio stood at 0.24 in 2020, then fell by 14.87% to 0.21 in 2021, then advanced by 29.66% to 0.27 in 2022, then slumped by 52.51% to 0.13 in 2023.
  • Business Quant data shows RXST's Debt Ratio at 0.13 in Q2 2023, 0.2 in Q1 2023, and 0.27 in Q4 2022.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Debt Ratio (Qtr)
1 Abbott Laboratories 201.40 Bn 194.75 Bn 6.27 Bn 0.31
2 Stryker 122.29 Bn 119.41 Bn 3.81 Bn 0.32
3 Medtronic 105.01 Bn 96.40 Bn 6.41 Bn 0.30
4 Boston Scientific 64.81 Bn 63.59 Bn 3.61 Bn 0.25
5 Edwards Lifesciences 55.28 Bn 51.60 Bn 1.29 Bn 0.04
6 Dexcom 29.06 Bn 27.94 Bn 750.30 Mn -
7 Koninklijke Philips 29.02 Bn 25.93 Bn 2.07 Bn 0.30
8 GE HealthCare Technologies 28.27 Bn 26.20 Bn 1.98 Bn 0.27
9 Smith & Nephew 25.80 Bn 25.22 Bn - 0.30
10 RxSight 221.81 Mn -196.39 Mn 23.50 Mn -

Historic Data

Download Data
DateValue
Jun 30, 2023 0.13
Mar 31, 2023 0.20
Dec 31, 2022 0.27
Sep 30, 2022 0.27
Jun 30, 2022 0.25
Mar 31, 2022 0.23
Dec 31, 2021 0.21
Sep 30, 2021 0.19
Jun 30, 2021 0.42
Dec 31, 2020 0.24